Last reviewed · How we verify
TESTOSTERONE CYPIONATE
At a glance
| Generic name | TESTOSTERONE CYPIONATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1978 |
Approved indications
Common side effects
- Acne
- Male pattern baldness
- Hirsutism
- Seborrhea
- Gynecomastia
- Penile erections (excessive frequency and duration)
- Nausea
- Headache
- Anxiety
- Depression
- Libido changes (increased or decreased)
- Injection site inflammation and pain
Serious adverse events
- Myocardial infarction
- Stroke
- Venous thromboembolism
- Hepatocellular neoplasms
- Peliosis hepatis
- Cholestatic jaundice
- Anaphylactoid reactions
- Central serous chorioretinopathy (CSCR)
- Suppression of clotting factors II, V, VII, and X
- Bleeding (with concomitant anticoagulant therapy)
Key clinical trials
- Body Composition Assessment in Transgender Population.
- Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC (PHASE2)
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (PHASE2)
- Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance (PHASE4)
- Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer (PHASE1)
- Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial) (PHASE2)
- Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone (PHASE1)
- Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TESTOSTERONE CYPIONATE CI brief — competitive landscape report
- TESTOSTERONE CYPIONATE updates RSS · CI watch RSS